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dsRNAcanbedetectedbypatternrecognitionreceptors,forexample,TLR3,MDA-5,NLRP3toinduceproinﬂammatorycytokines
responsible for innate/adaptive immunity. Recognized by endosomal TLR3 in myeloid DCs (mDCs), dsRNA can activate mDCs
into mature antigen presenting cells (mAPCs) which in turn present antigen epitopes with MHC-I molecules to na¨ ıve T cells.
Coadministration of protein and synthetic dsRNA analogues can elicit an antigen-speciﬁc Th1-polarized immune response which
stimulates the CD8+ CTL response and possibly dampen Th17 response. Synthetic dsRNA analogues have been tested as vaccine
adjuvant against viral infections in animal models. However, a dsRNA receptor, TLR3 can be expressed in tumor cells while
other members of TLR family, for example, TLR4 and TLR2 have been shown to promote tumor progression, metastasis, and
chemoresistance. Thus, the promising potential of dsRNA analogues as a tumor therapeutic vaccine adjuvant should be evaluated
cautiously.
1.Introduction
Pathogens on invading host cells express molecules that
are broadly shared by all microbes and distinct from host.
These include lipopolysaccharide, peptidoglycan, ﬂagellin
and microbial nucleic acids, and collectively are referred to
as pathogen-associated molecular patterns (PAMPs) [1–3].
Pattern recognition receptors (PRRs) of the host when rec-
ognizing PAMPs trigger a release of inﬂammatory cytokines
and type I interferons (IFNs) [4, 5]. PRRs are evolutionally
conserved and have been investigated extensively [4]. From
the initial investigation of Toll-like receptor (TLR) family
[6] to the recent discoveries of retinoic acid-inducible gene-
I (RIG-I)-like receptors (RLRs) [7, 8] and the nucleotide-
binding domain and leucine-rich repeat containing gene
family (NLRs, also known as NOD-like receptors) [9, 10],
all the evidence point to an important role in host defense.
TLRs are membrane bound receptors that sense PAMPs
on the cell surface or in endosomes [11] while RLRs and
NLRs recognize microbial molecules in the host cytosol
[12]. The individual members of these PRRs families are
characterized by their ligand speciﬁcity, cellular localization
and activation of unique downstream signaling pathways.
Immunity against diﬀerent microbial pathogen primarily
depends on the recognition of the speciﬁc PAMP of the
pathogen by the corresponding PRR.
Double-stranded RNA (dsRNA), a virus replication
intermediate and a signature of infection, is sensed by TLR3,
two members of RLRs family, that is, the RNA helicases RIG-
I and melanoma diﬀerentiation-associated gene 5 (MDA-5),
and the NLR pyrin domain (NLRP) 3 protein of NLR family.
These trigger the release of inﬂammatory cytokines, that is,
activating innate immunity which shapes adaptive immune
response [11, 13, 14]. The primary cytokines involved in
this response are type I IFNs including IFN-α and IFN-β
[15].
In this review, the mechanism of innate and adaptive
immunity induced by dsRNA and the potential application
of dsRNA as a vaccine adjuvant against viral infection and
anticancer immunotherapy is elaborated.2 Journal of Biomedicine and Biotechnology
2.dsRNA InducedSignaling
2.1. The TLR3-Mediated Signaling. TLRs are type I integral
membrane glycoproteins which have a trimodular structure
composed of an extracellular domain, a single transmem-
brane domain and an intracellular Toll/IL-1 receptor (TIR)
domain [11, 16, 17]. Twelve members of TLR family
have been identiﬁed in mammals [11]. The extracellular
N-terminal domains of TLRs contain 16–28 leucine-rich
repeats (LRRs) [16, 18] in a horse-shoe structure [17]. Each
individual LRR is composed of 20–30 amino acids with a
conserved characteristic repetitive sequence pattern rich in
leucines, the “LxxLxLxxNxL” motif and two or more repeats
in tandem, form curved solenoid structures suitable for
protein-protein interactions [19]. The extracellular domain
of human TLR3 comprises of 23 LRRs in a horse-shoe
shapedstructure.Theconvexfaceoftheextracellulardomain
of TLR3 is glycosylation-free and contains many positively
chargedresidueswhiletheconcavefaceislargelyglycosylated
and negatively charged [20, 21]. The dsRNA binding site
of TLR3 is located in two regions near the N-terminus
and C-terminus. When dsRNA interacts, two ectodomains
of TLR3 are connected by dsRNA in an “m” shape to
form a TLR3-dsRNA 2:1 complex [22]. When combined
with TLR3, dsRNA spans the whole “m” consisting of two
“horse-shoes” of the ectodomains of TLR3 (Figure 1A).
This satisﬁes the minimum requirement of 40–50 base
pairs of dsRNA allowing stable binding to TLR3 inducing
signaling [16, 23, 24]. With the secondary structure, the
transmembrane domain of TLR3 is a single α-helix and
the endodomain is composed of a ﬁve-stranded β-sheet
surrounded by ﬁve α-helics that forms the TIR domain
[25]. The B-B loop that connects β-strand B with α-helix
B in the TIR domain is considered the essential structure
that directly interacts with the adaptor protein TIR domain-
containing adaptor inducing IFN-β (TRIF) [26]. In addition
to the B-B loop, three boxes of conserved residues that
reside in TIR domain are involved in TLR3 signaling [25,
27].
TLR3 can be found both intracellularly and on the cell
surface in human ﬁbroblasts and epithelial cells. However,
it is predominantly located in intracellular vesicles, for
example, endosomes, in most cell types including dendritic
cells and macrophages [28, 29]. TLR3 is activated by
extracellular dsRNA that is released from dsRNA viruses or
is produced during single-stranded RNA viruses’ replication
orcomesfromapplicationofsyntheticdsRNAanalogues[4].
It is largely unknown how extracellular dsRNA are delivered
to the intracellular vesicles containing TLR3. Studies have
suggested that CD14 may play an important role in dsRNA
uptake [20, 30]. Once internalized into the endosome,
dsRNA binds to its adaptor protein TLR3 and activates
several signaling pathways. Upon binding to dsRNA, the B-B
loop of the TLR3 TIR domain combines with TIR domain
of TRIF activating several transcription factors, including
nuclear factor-κB( N F - κB), interferon regulatory factor 3
(IRF3), and activating protein 1 (AP-1) [25].
There are two pathways to activate NF-κB mediated by
receptor-interacting protein 1 (RIP1) and tumor necrosis
factor (TNF) receptor-associated factor 6 (TRAF6) (Figure
1A). TRAF6 is a ubiquitin ligase and plays a role in RIP1
polyubiquitination[31,32].PolyubiquitinatedRIP1isrecog-
nized by ubiquitin receptors, the transforming growth factor
β-activating kinase (TAK) binding protein (TAB) 2 and 3,
which in turn activate TAK1 [33]. IκB kinase-related kinase
α (IKKα)a n dI K K β are phosphorylated by the activated
TAK1. This leads to phosphorylation and degradation of
IκB, an inhibitor of NF-κB, and eventually results in the
translocationofNF-κBtocellnucleus.Thisisfollowedbythe
activation of speciﬁc gene promoter A20. TAK1 also activates
the 2 other classes of kinase, JNK and p38 and these activate
thefamilyofAP-1transcriptionfactors[27].Thethirdsignal
comesfromTRIFactivatingIRF3(Figure 1A).TRIFactivates
the kinase complex TRAF family member-associated NF-
κB activator (TANK)-binding kinase 1 (TBK1) and IKKε
through its adaptor protein, NF-κB activating kinase (NAK)-
associated protein 1 (NAP1), leading to the phosphorylation
and nuclear translocaton of IRF3 consequently inducing the
expressionofIFN-β [34].InadditiontoNAP1,TRAF3isalso
part of the TBK1/IKKε complex that is involved in the TRIF-
mediated IRF3 activation [35]. Another signal from TLR3
is related to the phosphorylation of two speciﬁc tyrosine
residues (Tyr759 and Tyr858) in the TLR3 TIR domain
whenTLR3interactswithTRIF(Figure 1A).Phosphorylated
Tyr759 recruits phosphatidylinositol 3-kinase (PI3K) which
then activates kinase Akt required for phosphorylation and
activation of IRF3 in nucleus [36]. The phosphorylation
of Tyr759 and also Tyr858 results in degradation of IκB
leading to NF-κB release and this induces phosphorylation
of NF-κB which partially activates it [37]. Tyrosine kinase
c-Src also plays a role in Akt activation [38]. The unique
signal pathway of TRIF is able to induce mammalian cell
apoptosis(Figure 1A).TRIFinteractswithFas-associatedcell
death domain (FADD) protein through RIP1 which in turn
activates procaspase-8 to initiate cell apoptosis [25, 39].
2.2. The RLRs-Mediated Signaling. RLRs are cytoplasmic
viral RNA sensors with three recognized members including
RIG-I, MDA-5 and laboratory of genetics and physiology 2
(LGP2). All belong to the DExD/H box RNA helicase family
[40]. In addition to the central helicase domain, RIG-I and
MDA-5 have two caspase recruitment domains (CARDs)
at its N-terminus which are responsible for downstream
signaling cascade through the interaction with a CARD-
containingadapter,mitochondrialantiviralsignalingadapter
(MAVS, also known as IPS-1, VISA, or Cardif) located in
the outer mitochondrial membrane [41]. LGP2, lacking the
N-terminal CARD, works as a negative regulator of RLRs
signaling. Although only a single CARD physically interacts
with MAVS, both CARDs are essential for downstream
signaling [42, 43]. The RIG-I activation is self-inhibited by
the C-terminal regulatory domain (RD), also referred as the
C-terminal domain (CTD) or repressor domain, through
intramolecular association between RD and both the CARD
and the helicase domains [42–44]. RD is also responsible
for the binding aﬃnity to the dsRNA and 5 -triphosphated
single-stranded RNA (5 ppp-ssRNA) of viral RNAs withJournal of Biomedicine and Biotechnology 3
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Figure 1: dsRNA induced signal pathways. (A) dsRNA signaling through TLR3. dsRNA that is internalized into endosome binds to TLR3.
The mechanism of dsRNA internalization is unknown, CD14 may play a role. TLR3 possesses two dsRNA binding sites near the N-terminus
and C-terminus. When combined with dsRNA, four dsRNA binding sites from two TLR3 molecules that are linked by the sole dsRNA
molecule in an “m” shape, and the B-B loop of the TLR3 TIR domain combines with the TIR domain of TRIF. The interaction of TRIF with
RIP1 or TRAF6 results in polyubiquitination of RIP1, the latter binds ubiquitin receptors TAB2 and TAB3 which activates TAK1. Activated
TAK1 induces phosphorylation of IKKα and IKKβ leading to phosphorylation and degradation of IκB. The release and translocation of
NF-κB to cell nucleus then occurs which results in the speciﬁc gene promoter A20 being activated. TAK1 also starts an activation sequence
beginning with JNK and p38, which activates c-JUN and ATF2 and this activates the AP-1 transcription factors family. TRIF activates TBK1
and IKKε through NAP1 and this results in phosphorylation and nuclear translocaton of IRF3 resulting in IFN-β production. TRAF3 also
binds with the TBK1/IKKε complex inducing IRF3 activation. Combination of TRIF results in phosphorylation of Tyr759 and Tyr858 in the
TLR3 TIR domain which subsequently induces the phosphorylation of, and degradation of IκB leading to NF-κB release. Phosphorylated
Tyr759 recruits PI3K and activates kinase Akt for full phosphorylation and activation of IRF3 in nucleus. Tyrosine kinase c-Src also plays a
role in Akt activation. TRIF interacts with FADD through RIP1 and activates procaspase-8 to initiate cell apoptosis. (B) dsRNA signaling
through MDA-5. dsRNA is recognized by MDA-5 in cytosol. MDA-5 interacts with MAVS located on the outer mitochondrial membrane via
CARD-CARD interaction leading to the dimerization of the MAVS N-terminal CARD domains which subsequently binds TRAF3 directly
through the interaction between the TRAF domain of TRAF3 and the TRAF-interacting motif in the PRR of MAVS. Then the RING
domain of TRAF3 forms a scaﬀold to assemble the noncanonical IKKs signal complex composed of TANK, TBK1, IKKε, NAP1 and NEMO.
This complex activates the signal-dependent phosphorylation of IRF3 and IRF7 to form a functional homodimer or heterodimer which
translocate to the nucleus to induce expression of type I IFN. TRAF2 and TRAF6 also associates with MAVS and is involved in activation of
P38 MAPK and promotion of IL-12 and type I IFN production or activation of NF-κB, JNK and P38 signaling. In addition, MAVS recruits
TRADD and interacts with TRAF3, TANK, FADD and RIP1 to activate both IRF3 and NF-κB signaling. (C) dsRNA signaling through NLRP3
inﬂammasome. NLRP3 recognizes dsRNA by a series of LRRs at the C-terminus. The NACHT domain at the middle of NLRP3 is related to
self-oligomerizationandtheformationofinﬂammasome.StudieshavesuggesteddsRNAmayactivatetheNLRP3inﬂammasome.Activation
of NLRP3 results in the interaction of NLRP3 PYD with ASC PYD, and in turn ASC CARD associates with pro-caspase-1 CARD and thereby
assembles the NLRP3 inﬂammasome. Once incorporated into NLRP3 inﬂammasome, pro-caspase-1 is activated by proteolytic cleavages to
remove the CARD prodomain. The active caspase-1 in turn cleaves the IL-1β, IL-18, IL-33 and IL-1F7 precursors into their active forms and
these active cytokines are secreted extracellularly.
a common core RNA binding site speciﬁcally adapted to
distinctanduniquepatterns[44–47].Itisalsoresponsiblefor
RIG-I dimerization. MDA-5 RD preferentially binds dsRNA
with blunt ends but does not associate with dsRNA with
either the 5  or 3  overhangs [13]. The central helicase
domain displays cooperative RNA binding properties [43,
48, 49]. The RD of MDA-5 does not exhibit self-inhibitory
activity [42, 50]. MDA-5 is negatively regulated by dihydrox-
yacetone kinase (DAK) and other possible regulators [51].
RIG-I binds 5 -triphosphate RNA in single- or double-
stranded forms [52–54] or short dsRNA of 300–1000bp
without a 5 -triphosphate [54] while MDA-5 recognizes long
dsRNA of more than 1000bp in length and the synthetic
dsRNA analogue polyinosinic-polycytidylic acid [poly (I:C)]
[54–56]. Upon sensing RNA, both RIG-I and MDA-5 are
activated and initiate downstream signaling through the
common pathway via adaptor protein MAVS (Figure 1B).
MAVS consists of a CARD at the N-terminus, a proline-
rich region (PRR) in the middle and a transmembrane
domain at the C-terminus attached to the outer surface of
mitochondria [57]. Activated RIG-I and MDA-5 associate
MAVS via a CARD-CARD interaction which leads to the4 Journal of Biomedicine and Biotechnology
dimerizationoftheMAVSN-terminalCARDdomains.Once
activated, binding to TRAF3 occurs directly through the
interaction between the TRAF domain of TRAF3 and the
TRAF-interactingmotif(TIM)inthePRRofMAVS[58–60].
Following the association of TRAF3 with MAVS, the RING
domain of TRAF3 forms a scaﬀold to assemble noncanonical
IKKssignalcomplexcomposedofTANK,TBK1,IKKε,NAP1
and NF-κB essential modulator (NEMO).This complexthen
activates the signal-dependent phosphorylation of IRF3 and
IRF7 to form a functional homodimer or heterodimer and
translocatestothenucleus[61,62].TheassociationofMAVS
and TRAF2 or TRAF6 has also similarly been demonstrated
[63]. TRAF6 is essential in the activation of NF-κB, JNK and
P38 signaling [64] while TRAF2 is involved in activation of
P38MAPKwhichpromotesIL-12andtypeIIFNproduction
[65]. Moreover, TNFR-associated death domain (TRADD)
is recruited to MAVS following virus infection and interacts
with TRAF3, TANK, FADD and RIP1 as well as activating
both IRF3 and NF-κB signaling [66]. Another protein-
termedstimulatorofinterferongenes(STING,alsoknownas
MITAorMYPS)expressedeitherontheoutermicochondrial
membrane [67] or endoplasmic reticulum [68] directly
interacts with RIG-I but not MDA-5. It subsequently recruits
TBK1activatingIRF-3.STINGhasbeenreportedtoassociate
with major histocompatibility complex class II (MHC II)
and mediates apoptotic signals via ERK activation [69].
It was recently reported that RIG-I binds to an adaptor
apoptosis-associatedspeck-likeproteincontainingacaspase-
activating and recruitment domain (ASC) to trigger caspase-
1-dependent inﬂammasome activation by a mechanism
independent of MAVS, CARD9 and NLRP3. This suggests
that RIG-I is able to activate the inﬂammasome in response
to certain RNA viruses [70].
2.3. The NLRs-Mediated Signaling via Inﬂammasome. NLRs
are intracellular PRRs sensing PAMPs and danger signals
or danger-associated molecular patterns (DAMPs) released
by injured cells [71]. The NLR family has 23 members in
humans and at least 34 members in mice [72]. NLRs are
multidomain proteins with tripartite structure composed of
an N-terminal eﬀector region, a central NACHT (Neuronal
Apoptosis inhibitory protein, NAIP; Class II transactivator,
CIITA; plant Het product involved in vegetative incom-
patibility, HET-E; Telomerase-associated protein 1, TP-1)
domain (also known as NOD domain), and a C-terminal
region for PAMPs recognition. The C-terminal region is
characterized by a series of LRRs and is implicated in ligand
sensing and NLRs autoregulation but the precise mechanism
is not clear [71]. The NACHT domain is a member of
signal transduction ATPases, part of the P-loop NTPase
family [73] and is related to self oligomerization and the
formation of inﬂammasome [71]. The N-terminal region
contains several protein interaction modules, such as acidic
domain, baculoviral inhibitory repeat (BIR)-like domain,
CARD and pyrin domain (PYD). Accordingly, NLRs are
further divided into subfamilies as NLRA, NLRB, NLRC
and NLRP. An additional subfamily, NLRX, is characterized
by the presence of an N-terminal domain with no strong
homology to any known domains of other NLR subfamily
member [74].
Upon recognition of PAMPs, toxins, or danger signals
by NLRs, a large protein complex termed the inﬂammasome
composed of NLRs, ASC and pro-caspase-1 is activated. This
protein platform activates pro-caspase-1 into its active form
of caspase-1 and this hydrolyzes pro-IL-1β and pro-IL-18
into theirmaturebiologicallyactiveformswhicharesecreted
extracellularly to play a role in immune response [14, 71].
Limited studies have suggested dsRNA is an activator of
NLRP3 inﬂammasome [75–78] although this has been dis-
puted [79]. NLRP3 senses PAMPs either from bacteria, such
as lipopolysaccharide (LPS), muramyl dipeptide (MDP),
bacterialpore-formingtoxinandbacterialDNAandRNA,or
fromvirusessuchasviralssRNAordsRNA,dsRNAanalogue
poly (I:C). It also senses other compounds such as imida-
zoquinoline antiviral drugs R837 and R848, nonmicrobial
signals encompassing uric acid crystals, calcium pyrophos-
phate dehydrate (CPPD), asbestos, silica, extracellular ATP,
alum adjuvant and ﬁbrillar amyloid-β [14, 71, 72, 80]. It
is believed that NLRP3 activation results in the interaction
of NLRP3 PYD with ASC PYD which in turn causes ASC
CARD to associate with pro-caspase-1 CARD assembling
the NLRP3 inﬂammasome (Figure 1C) [81]. Besides NLRP3,
ASC and pro-casepase-1, human NLRP3 inﬂammasome
contains a CARD-containing protein, CARD inhibitor of
NF-κB-activating ligands (Cardinal, also known as CARD8).
However, there is no homologue of Cardinal in the mouse
[81–83]. Allen et al. (2009) utilized small heteroduplex RNA
(shRNA) to knockdown the expressions of ASC, NLRP3 and
Cardinal respectively in human THP-1 monocyte cell lines.
The IL-1β production triggered by lentivirus infection was
signiﬁcantly attenuated by the addition of shRNA of ASC
or NLRP3. In contrast, secretion of IL-1β was not aﬀected
by knockdowns of Cardinal. Thus, it has been suggested
that Cardinal may not aﬀect NLRP3 inﬂammasome function
[77]. Furthermore, Cardinal does not bind to NLRP3 in the
inﬂammasome [84].
The activation of the NLRP3 inﬂammasome has been
demonstrated through a number of mechanisms. However,
the direct ligand for NLRP3 has yet to be deﬁned. It has been
proposed that the activation of the NLRP3 inﬂammasome
requires both microbial molecules and a second signal
such as extracellular ATP or pore-forming molecules [72].
Alternatively, it has also been suggested that reactive oxygen
species (ROS) may be the common NLRP3 inﬂammasome
activator since the most striking features associated with
NALP3 activators like potassium eﬄux and the induction
of frustrated phagocytosis all leads to ROS production
via NADPH [71, 85, 86]. In particular, the activation of
NLRP3inﬂammasometriggeredbyvirusinfectionorbypoly
(I:C) requires sensing viral RNA or poly (I:C), lysosomal
maturation, cathepsin B and ROS generation [77]. The
assembly of NLRP3 inﬂammasome leads to the activation of
pro-caspase-1andconsequentlythematurationofpro-IL-1β
and pro-IL-18 (Figure 1C).
Caspases belong to a conserved metazoan aspartate-
speciﬁc cysteine proteases family with 11 members in human
(caspases 1 to 10, and 14) and 10 members in murine speciesJournal of Biomedicine and Biotechnology 5
(caspases 1, 2, 3, 6, 7, 8, 9, 11, 12, and 14) [87, 88]. All
caspases are synthesized as inactive zymogens containing a
prodomain and are divided into two subfamilies: initiator
caspases and eﬀector caspases based on the length of their
prodomains. Initiator caspases (caspases 1, 2, 4, 5, 8, 9,
10, 11, 12) are involved in the interaction with upstream
adapter molecules and possess long prodomains that contain
either the death eﬀector domain or CARD. Eﬀector caspases
(caspases 3, 6, 7) that possess short prodomains are activated
by upstream caspases and are able to cleave multiple cellular
substrates involved in apoptosis [87]. Caspase-1, along
with caspases 4, 5, 11, and 12 are often referred to as
proinﬂammatory caspases. Once incorporated into NLRP3
inﬂammasome, pro-caspase-1 is activated by proteolytic
cleavage to remove the CARD prodomain. The active
caspase-1 in turn cleaves the IL-1β, IL-18, IL-33 and IL-1F7
precursors into their active forms and these active cytokines
are secreted extracellularly and become immunoreactive
(Figure 1C) [89].
It was recently reported that inﬂuenza virus infec-
tion results in the activation of NLR inﬂammasomes in
the lung. Although NLRP3 is required for inﬂammasome
activation in certain cell types, adaptive immunity to
inﬂuenza virus is ASC and caspase-1 dependent rather
than NLRP3 dependent, suggesting a central role of ASC
inﬂammasomes. The investigators concluded that inﬂuenza
virus infection stimulates NLRP3-dependent and NLRP3
independent inﬂammasomes in a cell type-speciﬁc manner
[90]. Moreover, it has been suggested that some viral RNA
can activate inﬂammasome via interaction between RIG-I
and adaptor ASC independent of NLRP3, MAVS, and CARD
[70].
3. Modulation of Adaptive Immunity by dsRNA
3.1. Activation of DCs. Activation of dendritic cells (DCs)
occursuponsensingdsRNA[91].DCse xp r essar epe rt o ir eo f
PRRsincludingTLRs(TLR3isnotexpressedinplasmacytoid
DCs), RIG-I and MDA-5 (absent in plasmacytoid DCs),
as well as NLRs, and are able to recognize a range of
pathogenic microbes [92–94]. The interaction of PAMPs and
PRRs on DCs induces the maturation and activation of DCs
via transcription, translation and secretion of inﬂammatory
cytokines and chemokines through the signal pathways
as described above. The activated DCs, characterized by
enhanced antigen presentation capacity and referred to as
antigen-presenting cells (APCs), migrate to draining lymph
nodes and interact with T and/or B lymphocytes initiating
the immunity process. Among the cytokines triggered and
secreted, type I IFN plays a major role in the cross-
priming of CD8+ T-cells by promoting the expression of
costimulatory molecules of DCs [95]. The proliferation
and diﬀerentiation of the lymphocytes are mediated by
signals from the activated DCs which comprise of the
co-presentation of MHC molecules and pathogen-derived
peptides. Additionally, signals from costimulatory molecules
including CD80 and CD86, as well as the instructional
signals, for example, IL-12p70 for Th1, IL-4 for Th2, and
IL-6 and IL-23 for Th17 from the presenting DCs [91]
are also present. dsRNA receptors which include TLR3
and RIG-I/MDA-5 are expressed in myeloid DCs (mDCs)
and primarily produce IL-12 and IFN-β when recognition
of dsRNA occurs [94]. However, poly (I:C) with diﬀerent
molecular weights have diﬀerential eﬀects on the maturation
of DCs [96]. Interestingly, co-culture of bone marrow-
derived DCs with protein and poly (I:C) reduced the antigen
uptake by DCs. However, the reduced uptake of antigen did
not aﬀect CTL priming by DCs suggesting that the reduction
in uptake of soluble antigen in the presence of poly (I:C) is
independent of TLR-mediated DC activation [97].
3.2. Activation of Th1 Cells. Newly primed CD4+ T-cells are
programmed by various cytokines and other factors from
DCs and other innate immune cells to diﬀerentiate into Th1
orTh2orTh17eﬀectorcellsorregulatoryT-cells(Treg)[98].
Th1 lymphocytes are produced by the na¨ ıve CD4+ T-cells
(Th0) interacting with IL-12 from mDCs to stimulate the
expression of signal transducer and activator of transcription
(STAT) 1 and subsequently that of T box expressed in T-
cells (T-bet). The latter is the critical transcription factor of
Th1 cells [99]. Activated Th1 cells produce cytokines like
IL-2 and IFN-γ that are cofactors in CD8+ CTLs activation
and synergistically activate mDCs acting via a feedback
loop. Signals from Th1 cells are essential for CD8+ T-cell
proliferation and function [99]. It is believed that dsRNA
is capable of inducing robust IL-12p70 production which
reduces the threshold of Th1 response and herein promotes
Th1-biased adaptive immunity through TLR3 and JNK
pathways [98, 100]. TNF-α, type I IFN and IL-18 also play
important roles in the induction of Th1 response by dsRNA
[101]. Type I IFN can activate mDCs directly by inducing
phenotypic maturation which includes but is not restricted
to upregulation of MHC Class I, class II, CD40, CD80, CD86
and higher expression of CD83 [102]. Besides inducing
mDCs maturation and activation, IFN-α/β upregulates the
expression of chemokine receptor CCR7 to sensitize mDCs
toCCL19andCCL21whichpromotethemigrationofmDCs
from peripheral tissues towards the T-cell area of lymphoid
organs [102]. Type I IFN is also necessary for the generation
of a Th1 CD4+ adaptive T-cell response whereas IL-12p40
and type II IFN are not. Therefore, the activation of Th1
cell response induced by dsRNA is possibly mediated by
its capacity of inducing robust type I IFN production [92].
However, at low concentrations of dsRNA (0.1–1μg/ml),
human lymphocytes express prototypic Th2 cytokine IL-4
[103]. Indeed, when coadministered with protein antigen, in
addition to the induction of robust Th1 biased immunity,
dsRNA is also capable of enhancing Th2 antigen-speciﬁc
immune response [104–106].
3.3. Activation of Cytotoxic T Lymphocytes. When stimulated
by dsRNA along with speciﬁc antigen, activated DCs are able
to induce antigen-speciﬁc CD8+ cytotoxic T lymphocytes
(CTLs) activation through cross-presentation and cross-
priming mechanism [91]. During viral infection of mDCs,
dsRNA is produced during replication in the infected mDCs6 Journal of Biomedicine and Biotechnology
and the latter in turn activates mDCs through TRIF, MAVS,
NLRP3 inﬂammasome and possibly another undeﬁned sig-
nal pathway(s) to become APCs. APCs present endogenous
antigens including those from intracellular viral origin
with MHC class I molecules to na¨ ıve CD8+ lymphocytes
along with costimulatory factors and instructional signals to
activate the lymphocytes becoming MHC-I restricted CTLs.
However, in most cases, the virus does not invade mDCs
directly but instead infects cells other than mDCs. In such
cases, the extrinsic viral antigen and dsRNA can be taken
up into mDCs and these mDCs in turn present the antigen
epitope with MHC-I molecules to CD8+ lymphocytes induc-
ing a CTL response. This mechanism is referred to as cross-
priming and inducible by TLR3-TRIF signaling and MDA-
5-MAVS signaling [107, 108]. Type I IFN produced through
these signal pathways also enhances the cross-priming ability
of mDCs possibly via augmenting their capacity to deliver
costimulatory signals [102] or directly stimulation of CD8+
T-cells [109] .T h em e c h a n i s mo fm D C su p t a k eo ft h ee x t r i n -
sic antigens involves phagocytosis of particulate antigen,
pinocytosisofsolubleantigenandreceptorsmediatingcross-
presentation such as Fc receptor, mannose receptor and
Dectin-1 [110]. The ability of cell-associated poly (I:C) with
antigen to induce robust cross-priming responses in na¨ ıve
mice is completely lost in the Tlr3-deﬁcient chimera mice
[107]. Immunized with protein along with alum and poly
(I:C), the expansion of antigen-speciﬁc CD8+ T-cell can be
reduced in both MAVS-deﬁcient and TRIF-deﬁcient mice
and entirely abrogated in the bideﬁcient mice [108]. Type I
IFN produced through TRIF or MAVS signal pathway also
enhancescross-priming bymDCs [102,109].Arecentreport
suggested that CD8+ T-cells can be activated by dsRNA
directly triggering TLR3 [111]. Priming of IFN-γ-producing
CD8+ T-cells by dying tumor cells failed in the absence of a
functional IL-1 receptor 1 and in Nlpr3-deﬁcient or caspase-
1-deﬁcient mice unless exogenous IL-1 was present [112].
This suggests that the NLRP3 inﬂammasome is involved in
the activation of CTLs.
3.4. Activation of Th17 Cells. Th17 cell is a proinﬂammatory
lymphocyte belonging to Th cell subset [113, 114]. This
subset preferentially produces IL-17, IL-17F, IL-22, and IL-
21, but not IFN-γ or IL-4 [115]. Na¨ ıve T-cells are induced
by transforming growth factor (TGF)-β to diﬀerentiate into
tworeciprocalsubsets,thatis,Th17cellsandTregcellsunder
diﬀerent polarizing signals. IL-6 is the polarizing signal of
Th17whichswitchesthetranscriptionalprograminitiatedby
TGF-β to induce the development of Th17 cells and blocks
the development of Treg cells [116–118]. IL-23 plays a role
in amplifying and stabilizing the phenotype of Th17 cells
[119]. However, receptors for IL-23 are not expressed in
na¨ ıve T-cells. In fact, Th17 cells can express such receptors
if induced by TGF-β acting through ROR-γt which is a
unique transcription factor of Th17 (the human counterpart
of murine ROR-γti sR O R - c )[ 120]. ROR-γt is the key
transcription factor that orchestrates the diﬀerentiation of
Th17eﬀectorcelllineage by inducing transcription of the IL-
17 gene in na¨ ıve helper T-cells and is also required for the
development of IL-17 producing cells in the presence of IL-
6a n dT G F - β [121]. IL-6 is involved in upregulation of IL-
23R mRNA expression, and IL-6 and IL-23 synergistically
augment its protein expression [122]. Therefore, IL-23 acts
on T-cells that are already committed to the Th17 lineage
rather than inducing Th17 diﬀerentiation.
Th17 cells are engaged in the neutrophil related inﬂam-
mation against infections of fungi and certain extracellular
bacteria [115]. Most parenchymal cells express IL-17 recep-
tors that interact with IL-17 that are expressed primarily
from Th17 cells to produce proinﬂammatory factors such
as IL-1, IL-6, IL-8, tumor necrosis factor (TNF) and matrix
metalloproteinases [115, 123]. Th17 cells can also induce
chemokine production which attracts numerous eﬀector T-
cells into inﬂammatory area promoting the inﬂammatory
response. Thus, inappropriate regulation of Th17 cells
activities is associated with chronic inﬂammation and severe
immunopathologic conditions such as autoimmunity [115].
Various studies have suggested that TRIF signal pathway
is involved in Th17 response. TRIF signaling in mDCs
might induce IL-12 and IL-23 production and play a role in
Th17 activation [124]. However, the TLR3 pathway activated
by dsRNA induces activation of IRF3 and IRF7 which
exclusively induce p35 and p28 but not p19. These in turn
would induce IL-12 (p35 and p40) and IL-27 (Epstein-Barr
virus-induced gene 3 and p28) but not IL-23 (p19 and p40)
[125]. Stimulation of endosomal TLR3 by poly (I:C) can
induce mDCs to produce both IL-12p70 and IL-27; the
former promotes Th1 cells to produce IFN-γ which can
inhibit Th17 cells generation and the latter inhibits Th17
cells diﬀerentiation in a STAT1-dependent manner. Thus,
poly (I:C) is likely to dampen Th17 responses [126]. TRIF-
dependent type I IFN production along with its downstream
signaling pathway negatively regulates Th17 development
and constrains Th17-mediated autoimmune inﬂammation
in mice [127]. It has also been reported that poly (I:C)
can induce synthesis of both IL-17 and IL-21 and drive
the diﬀerentiation of na¨ ıve Th cells into an IL-21 but not
into an IL-17-producing phenotype without aﬀecting the
levels of transcription factors T-bet, GATA-3, or retinoic acid
receptor-related orphan receptor C [128]. Thymic stromal
lymphopoietin (TSLP) is a hemopoietic cytokine capable of
conditioning mDCs and orientating the diﬀerentiation of
na¨ ıve T-cells towards a Th2 proﬁle. mDCs activated by a
combination of TSLP and poly (I:C) are capable of priming
na¨ ıve CD4+ T-cells to diﬀerentiate into Th17-cytokine-
producing cells with a central memory T-cell phenotype
without changing the Th2 polarization property of TSLP
[129].
4. PotentialApplication of dsRNA
asa Vaccine Adjuvant
4.1. The Adjuvant Properties of dsRNA. Innate immu-
nity shapes adaptive immunity. Activated immune cells
present speciﬁc antigen epitope associated with MHC-
I/II molecules along with costimulatory and instructional
signals to na¨ ıve T-cells to stimulate activation, diﬀerentiationJournal of Biomedicine and Biotechnology 7
and proliferation of immunoreactive T-cells. As a potent
activator of both innate and adaptive immunity, dsRNA
simultaneously administered with a foreign antigen can act
as an immunoadjuvant to induce speciﬁc adaptive immunity
against the foreign antigen [91, 130].
Upon dsRNA stimulation, type I IFN production by DCs
is critical for the adjuvant property of poly (I:C) [92]. Type
I IFN is considered to be the major player linking innate to
adaptive immunity. Besides activating DCs in an autocrine
or paracrine manner, type I IFN is capable of inducing
an antigen-speciﬁc CD8+ T-cell response, a CD4+ Th1 cell
response and enhances the primary antibody response [2].
Salaun et al. (2009) demonstrated that proliferation and
IFN-γ production of antigen-speciﬁc CD8+ T-cells in the
mice immunized by antigen GP33 (an H-2Db restricted
peptide derived from Lymphocytic Choriomeningitis virus
glycoprotein 33–41) with poly (I:C) adjuvant is abrogated
when this regimen is administered in TLR3−/− mice [131].
The mRNA of TLR3 is undetectable in either CD8+ eﬀector
or CD8+ eﬀector memory T-cells. CD8+ T-cell proliferation
and the ability of INF-γ production are not aﬀected by direct
stimulation with poly (I:C) and speciﬁc TCR. Therefore,
it appears that the adjuvant eﬀect of poly (I:C) may be
TLR3-dependent without any direct eﬀect on CD8+ T-
cells [131]. However, Ngoi et al. (2008) experimenting on
(C57BL/6) mice that were TLR3−/− and TRIF-deﬁcient, with
the poly (I:C) (InvivoGen) but using a diﬀerent antigen,
staphylococcal enterotoxin A, showed that CD8+ T-cells
expansion was not impaired, that is, a type I IFN production
in response to poly (I:C) occurred [132]. Splenocytes from
na¨ ıve wild-type mice can produce IL-10 in a dose-dependent
manner upon stimulation with poly (I:C) in the absence of
antigen while IL-10 production was impaired in TLR3−/−
mice. Although these IL-10 producing cells may be innate
immune cells, the IL-10 produced acts as a suppressive
signal for adaptive immunity. Thus, the presence of TLR3
may suppress the development of adaptive immunity [132].
Indeed, the activation of NK cells, involved in innate
immunity, is inducible by poly (I:C) via both MAVS- and
TRIF-dependentpathways[133].Kumaretal.[108]reported
that in MAVS-deﬁcient or TRIF-deﬁcient mice immunized
with OVA, alum and poly (I:C), the antigen-speciﬁc CD8+
T-cell expansion was reduced in either MAVS-deﬁcient or
TRIF-deﬁcientmiceandwasentirelyabrogatedinthedoubly
deﬁcient mice. Hence, the adjuvant eﬀects of poly (I:C)
requires a cooperative activation of TLR and cytoplasmic
RNA helicase pathways [108]. Contamination of proteins
used as antigens in these studies with other TLR ligands [93]
or the contamination of CD8+ T-cells with other immune
cells like innate cells might be a possible explanation of the
discrepancy.
With respect to human CD8+ T-cells, TLR3 mRNA
e x p r e s s i o nh a sb e e nd e t e c t e di nh u m a ne ﬀector and eﬀector
memory cells but not in na¨ ıve and central memory T-cells
[134]. The addition of poly (I:C) signiﬁcantly increased
the quantity of IFN-γ released by eﬀector and/or eﬀector
memory CD8+ T-cells in response to PHA in a dose-
dependent manner. However, poly (I:C) by itself did not
detectably induce IFN-γ release by any of the puriﬁed CD8+
T-cellsubsets.Furthermore,theadditionofpoly(I:C)hadno
eﬀect on the cytolytic activity of CTL. Therefore, it is likely
that the adjuvant eﬀects and the corresponding mechanism
of poly (I:C) are diﬀerent in human and mouse cells.
4.2. dsRNA as Vaccine Adjuvant against Viral Infection. Lau
et al. (2009) reported that mice vaccinated with H5N1
inﬂuenzavaccinewithPIKA(astabilizeddsRNA)asadjuvant
experienced a maximum three-fold increase in antibody
titer comparable to that produced by mice immunized by
vaccine with complete Freund’s adjuvant [135]. Vaccination
signiﬁcantly reduced the virus titer in the lung of mice
challenged after immunization with the H5 vaccine and
PIKA adjuvant. Without a speciﬁc vaccine, sole PIKA
administration was also capable of reducing pulmonary viral
titer in mice [135]. This immunoprotective property of
dsRNA against inﬂuenza virus was further demonstrated by
other studies using another synthetic dsRNA analogue poly
ICLC comprising of poly (I:C) stabilized with L-lysine and
carboxymethylcellulose [136, 137]. PIKA was also able to
induce activation and proliferation of B cells and NK cells.
When HBsAg was coadministered, an increase in HBsAg-
speciﬁc IgG production was noted. However, PIKA did not
activate CD4+ and CD8+ T-cells [138]. Nonetheless, most
studies suggested that poly (I:C) based dsRNA analogues
displayed Th1 adjuvant property capable of activating anti-
gen speciﬁc CD4+ and CD8+ T-cells when administrated
as vaccine adjuvant [92, 105, 131, 132, 139, 140]. Another
dsRNA analogue, poly (I:C12U) (Ampligen), was eﬀective
in inducing mDCs maturation and promoted Th1 cytokine
IL-12 production while signiﬁcantly decreased suppressive
cytokine IL-10 production compared to that induced by
poly (I:C) in healthy donors [140]. Intranasal administration
of an Ampligen adjuvanted H5N1 vaccine resulted in the
secretionofvaccine-speciﬁcIgAandIgGinnasalmucosaand
serum respectively and protected mice against homologous
and heterologous viral challenge [141]. Immunization of
mice by hepatitis C virus nonstructural protein 3 and poly
(I:C) emulsiﬁed with Montanide ISA 720 have demonstrated
that the protein-based vaccine adjuvant, poly (I:C) was
capable of eliciting Th1-biased adaptive immunity although
the protein-based vaccine alone favors Th2-polarization.
Additionally, the adjuvant potency of poly (I:C) emulsiﬁed
with Montanide ISA 720 was much stronger than that of
dispersed delivered poly (I:C) which suggests that protection
of poly (I:C) from rapid degradation by ribonucleases was
crucial for the adjuvant property of poly (I:C) [105]. Other
groups have also suggested an Th1 adjuvant role of poly
(I:C) [92, 139]. More importantly, induction of CD4+ Th
cells by poly (I:C) is required for memory in CD8+ T
lymphocytes [142]. CD8+ C T Lm e m o r yp l a yi m p o r t a n t
roles in vaccine design for prevention of viral infection.
Therefore, it seems that the adjuvant property of distinct
dsRNA molecules may be diﬀerent as suggested by Avril et al.
[96].
Several synthetic dsRNA analogues are commercially
available such as poly (I:C), poly (I:C12U), poly ICLC, poly
(A:U) and PIKA. Poly (I:C) is a mismatched dsRNA with one8 Journal of Biomedicine and Biotechnology
strand being a polymer of inosinic acid, the other a polymer
of cytidylic acid. It was discovered in 1967 by Hilleman’s
group [143] who also discovered IFN induction by dsRNA
[144] before the discovery of its molecular receptors of TLR3
[145]a n dM D A - 5[ 56, 146]. However, toxicity concerns
prevent the clinical utility of poly (I:C) [147–149]. Thus,
most studies using poly (I:C) as an immunoprotective or
vaccine adjuvant have been undertaken in animals. Attempts
to design dsRNA analogues that can induce IFN with less
toxicity have resulted in poly (I:C13U) being modiﬁed to
poly (I:C12U) [150]. Poly (I:C12U) diﬀers from poly (I:C)
in that every 13th cytosine of the dsRNA, cytosine (C) is
replaced by uracil (U). Uracil is unable to bond hydrogen
to the hypoxanthine of the partner poly (I) strand and
therefore results in a mismatched base which would be more
readily degraded than the parent molecule [147]. This poly
(I:C) analogue has been applied in clinical trials for chronic
fatigue syndrome and AIDS. It was generally well-tolerated
via intravenous administration with insomnia and dry skin
the most commonly reported adverse events [151]. It also
exhibited profound and uniformly suppressive eﬀects on
HIV expression in vivo [152]. Poly ICLC was introduced by
Levy et al. in 1975 and comprised of poly (I:C) with poly-
L-lysine and carboxymethylcellulose [153]. This complex
is 5–10 times as resistant to hydrolysis by primate serum
as the parent poly (I:C) and has a thermal denaturation
temperature about 40◦C higher than that of poly (I:C). It
was able to induce signiﬁcant levels of serum IFN in monkey
and chimpanzee under conditions in which poly (I:C) itself
induced no IFN [153]. In an early clinical trial in patients
with malignancy, toxic reactions composed of fever, nausea,
hypotension, thrombocytopenia and leukopenia, erythema,
polyarthralgia with myalgia [154]. PIKA is a stabilized
dsRNA greater than 100 base pairs in length [135]. Clinical
information regarding PIKA is limited and the available data
are only from animals [135, 138, 155]. Stahl-Hennig et al.
(2009) reported that poly (I:C) and its analogues poly ICLC
and poly (I:C12U) are eﬀective adjuvants for the induction
of protein-speciﬁc cellular immune responses [104]. Among
the three molecular analogues, poly ICLC was the most
potent adjuvant in monkeys. This may be attributed to poly
ICLC being more stable against primate serum nucleases.
Another study using HIV gag as antigen showed that both
poly(I:C)andpolyICLCwereabletoinduceantigen-speciﬁc
CD4+ T-cell response without IL-4 and IL-17 secretion,
conﬁrming Th1-polarized adjuvanticity. This adjuvant role
is type I IFN-mediated [92]. Gowen et al. [156] revealed
that poly (I:C) treatment signiﬁcantly protected TLR3−/−
mice from the lethal Punta Toro virus infection despite
deﬁciencies in cytokine induction while poly (I:C12U) was
unable to protect TLR3−/− mice from lethal challenge. It
failed to produce IFN-α,I F N - β, and IL-6. However, in wild-
type mice, poly (I:C12U) treatment was able to promote
IFN-α,IFN-β,andIL-6productionandconferredprotection
from Punta Toro infection [156]. These results suggested
that both TLR3 and MDA-5 are required for poly (I:C) to
elicit immune responses but poly (I:C12U) requires only
TLR3. This conclusion was veriﬁed later by Trumpfheller et
al. (2008) [139]. Distinct forms of poly (I:C) with diﬀerent
molecular weights or poly (I:C12U) are not equivalent in
their biological behavior [96].
4.3. dsRNA as Vaccine Adjuvant against Cancer. DCs and
macrophages are major sensor cells to invading pathogen
and transformed cells via germ-line encoded PRRs. Upon
sensing pathogens or tumor cells, activation involves these
cellsbecomingAPCstriggeringinnateimmunityandthereby
shaping adaptive immunity through cross-priming to elimi-
nate the invading microbes and tumor cells. Cancer cells are
malignantly transformed cells of the host and are capable of
expressing antigensthatarenotexpressedorintraceamount
in healthy host and are referred to as tumor associated
antigens (TAAs) [157]. Adaptive immunity is the major
mechanism to eliminate cancer cells in the late stage of
host defense responses by the generation of tumor-speciﬁc
immunity [158]. Various reports have demonstrated that
the recruitment of tumor inﬁltrating lymphocytes, especially
CD8+ T-cells, is closely related to prognosis of the patients
[159–161]. However, the anticancer immunity of the tumor-
bearing host is usually weak or anergic due to either the weak
antigenicity of TAAs or because of suppressive immunity
in the host. Thus, enhancing the immune response, in
particular TAA-speciﬁc CTL response and overcoming the
immune suppression is crucial for anticancer immunity.
Indeed, Provenge (also known as sipuleucel-T or APC8015)
(Dendreon, Seattle, WA), a new cancer vaccine for advanced
prostate cancer, was recently approved by FDA at April
29, 2010 [162]. Provenge works by ex vivo stimulation of
isolated autogenous DCs of the patient with a fusion protein
of full-length human prostatic acid phosphatase (PAP)
and granulocyte-macrophage colony stimulating factor. This
stimulation of DCs results in activation of APCs. The PAP
activated APCs are suspended in lactated Ringer’s solution,
after removing the excessive antigen, and then infused into
thepatientresultingininnateandadaptiveimmunityagainst
cancer cells [163]. Clinical trials have shown statistically
signiﬁcant prolonged median survival times [163–165]. This
is the ﬁrst FDA approved therapeutic tumor vaccine [166].
TLRs have been involved in the immunotherapy for
cancer. Agonists of TLRs with the capacity of priming
and shaping adaptive immunity have aroused signiﬁcant
interest in the development of cancer immunotherapy,
in particular imiquimod, unmethylated cytosine preceding
guanosine motif oligodeoxynucleotides (CpG ODNs), and
dsRNA which act as agonistically with TLR7, TLR9, and
TLR3, respectively [167].
Activation of TLR3 by dsRNA was capable of inducing
either anticancer immune response or cancer cells apoptosis
via TLR3 receptor expressed on a variety of cancer cells
[168–173]. The two mechanisms of dsRNA against cancer
work synergistically. Apoptosis of cancer cells presents the
immune system with a new repertoire of TAAs in a TLR3
activation context that is favorable to the development of
long-term anticancer immune responses. Poly (I:C12U) is
capable of inducing phenotypic and functional maturation
of DCs generated from peripheral blood monocytes of
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IL-12p70 production. DCs primed with tumor lysate and
matured with poly (I:C12U) are capable of generating Th1-
biased speciﬁc anticancer responses in peripheral blood
T-cells derived from cancer patients in the presence of
ascites medium containing immunosuppressive cytokines.
Using ovarian cancer ascites as an in vitro model, CD8+ T-
cells derived from ascites ﬂuid primed with tumor antigen
loaded DCs matured with poly (I:C12U), exhibited cytotoxic
activity with the capacity of lysis of autologous tumor cells
[140, 174]. Another synthetic poly (I:C) derivative, poly
ICLC, more eﬀective as an type I IFN inducer in humans
but also associated with more clinical side-eﬀects [175], has
been involved in a variety of clinical trials of malignancy
treatment in the last 30 years [176–180]. When poly
ICLC was used either in monotherapy or in combination
therapy, it exhibited immunomodulatory eﬀects [181]a n d
enhancement of IL-2-induced NK lytic activity in cancer
patients [179]. However, sole poly ICLC administration did
not improve the survival of cancer patients [177, 179, 180].
Despite the unfavorable results of poly ICLC in tumor
therapy, auspicious results were noted when used as a
cancer vaccine adjuvant in mice [182]. When poly ICLC was
administered with tumor antigen-derived peptide epitopes
as a cancer vaccine adjuvant in a murine brain tumor
model, it was capable of enhancing antigen-speciﬁc CTL
response. This facilitates the inﬁltration of antigen-speciﬁc
T-cells into the tumor site, promotes tumor homing of
antigen-speciﬁc T-cells and improves the survival of tumor-
bearing mice by inducing long term antitumor protection
[182]. A phase I/II clinical trial using type I polarizing DCs
loaded with peptides in combination with poly ICLC in
patients with recurrent malignant glioma is currently being
conducted [183].Polyadenylicpolyuridylicacid[poly(A:U)]
is another type of synthetic dsRNA analogue that has been
usedincombinationwithchemotherapyforlocallyadvanced
gastric cancer after curative surgery patients compared with
chemotherapy alone [184] despite of its ineﬃciency as a
single adjuvant [185] .Ap r o l o n g e do v e r a l la n dr e c u r r e n c e -
free survival was noted. Poly (A:U) is capable of inducing
Th1 cell generation and antibody production in mice when
coadministered with protein [186]. In vivo targeted delivery
of tumor associated epitope to APCs in conjunction with
poly (A:U) resulted in correction of the ineﬀective response
toidiotypicepitopes,controloftumorgrowth,establishment
of immune memory and protection against tumors bearing
antigenic variants [187]. The immunoadjuvant eﬀects of
poly (A:U) is believed to signal TLR3 and TLR7 [188].
TLR3 agonists may be an double-edged sword in cancer
treatment [189]. TLR3 expresses not only on immune
cells sensing dsRNA and triggering immune response but
also on tumor cells exhibiting other functions [190]. It
is well known that viral infection is closely related with
carcinogenesis and approximately 20% of all cancers are
associated with infectious agents [191]s u c ha sh u m a n
papillomavirus [191] and hepatitis viruses [192]. Preven-
tion of viral infection is able to signiﬁcantly reduce the
occurrence rate of cancer [193–195]. Inhibition of virus
replication reduced the development of cancer dramatically
even in chronically viral infected patients [194, 196]. In
this scenario, it is suspected that dsRNA, as intermediate
of viral replication, is involved in the carcinogenesis. Long
before the discovery of TLR3, researchers have found that
dsRNA,suchaspoly(A:U)treatmentiscapableofenhancing
carcinogenesis in animals [197, 198] .S t u d i e sh a v es u s p e c t e d
that activation of TLRs in cancer cells could promote tumor
progression and chemoresistance by activation of NF-κBt o
induce upregulation of antiapoptotic proteins and to inhibit
proapoptotic proteins [190]. Consistently, several groups
have reported that TLR agonists stimulate the proliferation
and suppressor function of Treg cells and so attenuate the
antitumor eﬀects [199, 200]. However, most studies were
conducted by activation of the TLRs other than TLR3 [190,
201, 202]. Recent reports suggested that TLR3 expression
is much higher in metastatic cancer cells in comparison
with primary cancer cells [169]. In human hepatocellular
carcinoma cells, TLR3 can be expressed both on cell surface
and in cytosol and only activation of the cytoplasmic TLR3
can induce cancer apoptosis accompanied by the down-
regulation of antiapoptotic protein [171]. In situ stimulation
of TLR3 and synergistic molecule CD40 can transform
ovarian cancer-inﬁltrating DCs from immunosuppressive
to immunostimulatory cells thus exhibiting therapeutic
potential of TLR3 activation [203]. Activation of TLR3 in
nasopharyngeal carcinoma cells can inhibit cell migration by
downregulation of chemokine receptor CXCR4 suggesting
antimetastasis activity of endogenous human TLR3 expres-
sion in cancer cells [204]. Thus, it seems that activation
of endogenous human TLR3 expressed by cancerous cells
may induce direct pro-apoptotic activity of the tumor cells
[168]. Additionally, mRNA escaping from damaged tissue
or contained within endocytosed cells could serve as an
endogenous ligand for TLR3 [205].
5.Perspectives
Double-stranded RNA and its synthetic analogues, such as
poly (I:C) and poly (A:U) have long been known to be
potent type I IFN inducers and immunomodulators [144].
However, the fact TLR3 recognized dsRNA and activates
NF-κB signal pathway was only discovered in 2001 [145].
Subsequently, other dsRNA receptors, RIG-I/MDA-5 and
NLRP3 have been uncovered [7, 75, 206]. Studies of the
interaction of dsRNA and its receptors have focused on
immune cells. It is unknown if there are any endogenous
ligands that share these receptors with exogenous dsRNA.
Additionally, dsRNA receptors especially TLR3 are found
expressed ubiquitously in the body. It is reasonable that not
all types of cells are involved in sensing viral infection and
eliciting immune response. Thus, the role of these receptors
in other type of cells deserves further exploration.
dsRNA is able to induce both innate and adaptive
immunitytoeliminatetheinvadingvirus.However,thevirus
may evolve protective mechanism that enables it to destroy
the dsRNA-induced signaling thereby protecting itself by
evasion from the immune response of the host [207, 208].
Thus, overcoming viral protective mechanism(s) is desirable.
There is insuﬃcient information regarding TLR3 acti-
vation in cancerous cells. Recent report suggested that10 Journal of Biomedicine and Biotechnology
poly (I:C) binds to endo/lysosomal MDA-5 and activates
apoptotic caspases in melanoma cells to induce their self
degradation by autophagy and apoptosis [209]. The pos-
sibility that other dsRNA receptors may be present in
tumor cells deserves further investigation. Having such
knowledge would be very helpful for development of ther-
apeutic tumor vaccine with dsRNA analogue adjuvant. In
addition, the eﬀects of dsRNA signaling on Treg cell are
not known. It appears that there needs to be a balancing
act between the possible carcinogenesis and the immune
stimulating property of dsRNA when dsRNA analogues are
considered as immunoadjuvants in tumor immunother-
apy.
Although dsRNA have displayed favorable immunostim-
ulatory and protective properties, many questions remain to
be answered. Further investigations to uncover its roles in
viral infection, carcinogenesis or anticancer actions deserve
consideration.
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